5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric CancersDigestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorderRecruitingPhase 12026-09-25NCT06663319
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid MalignanciesneoplasmActive, not recruitingPhase 12026-09-25NCT04606381
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung CancerNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 12026-09-02NCT07027514
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMRcardiovascular disorder, heart disorder, heart failure, heart valve disorder, mitral valve insufficiencyRecruitingNot applicable2026-04-13NCT03142152
A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerChromosomal Instability, Chromosome Aberrations, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Genomic Instability, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, head and neck squamous cell carcinoma, neoplasm, ovarian carcinosarcoma, skin disorder, squamous cell carcinoma, triple-negative breast carcinoma, uterine carcinosarcoma, uterine disorderRecruitingPhase 1 / Phase 22025-11-04NCT05902988